Arcutis Biotherapeutics

ARQT

Market cap $3.23B

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativa Initiation of clinical development program for ARQ-234 in atopic dermatitis Transition to positive cash flows enables investment to both accelerate growth of ZORYVE franchise and advance pipeline WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced its strategic priorities for 2026.

New York City-based Suvretta Capital Management sold nearly 1.1 million ARQT shares during the third quarter. The move contributed to a decline in the overall position value by about $35.78 million.

Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.

Arcutis already has its key drug approved for various diseases and concentrations. Sales are expanding rapidly, and Arcutis is positioned for growth.

Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD.

Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $1.69B estimate, supporting a bullish outlook. ARQT's Q3 net income reached $7.4M, with cash flow break-even now expected in Q4, de-risking the investment case.

Investors need to pay close attention to ARQT stock based on the movements in the options market lately.

Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance for Zoryve.